Previous Renal Replacement Therapy Time at Start of Peritoneal Dialysis Independently Impact on Peritoneal Membrane Ultrafiltration Failure

Table 2

Comparison between acquired UFF group and stable patients (categorical data as number (percentage) compared by Fisher’s exact test; continuous data presented as median (25%–75% interquartile range), compared by Mann Whitney 𝑈-test); Δ Ca125 is the variation between last evaluation in the followup and baseline effluent CA125 U/min levels.

	Acquired UFF	Stable group	𝑃
	𝑁=7	𝑁=108
Sex (male) (𝑁; %)	5 (71.4%)	39 (36.1%)	0.104
Diabetes (𝑁; %)	0 (0%)	22 (20.4%)	0.343
Age	39 (34–45)	48 (35–60)	0.179
Comorbidity score (≥2)	2 (28.5%)	28 (25.9%)	0.203
RRT time (months)	77 (13–147)	0 (0–33)	0.003
Baseline GFR mL/mn	0 (0–3.6)	5.1 (1.37–7.4)	0.009
APD (Yes)	5 (71.4%)	61 (56.5%)	0.697
Peritonitis (Yes)	7 (100%)	61 (56.5%)	0.040
Peritonitis (𝑛)	3 (1–4)	1 (0–2)	0.008
PET parameters
D/P creatinine	0.78 (0.75–0.94)	0.71 (0.64–0.81)	0.037
D/D0 glucose	0.24 (0.18–0.30)	0.30 (0.30–0.34)	0.021
PET drainage	2300 (2250–2400)	2800 (2600–2900)	<0.0001
D/P Na 60	0.92 (0.88–0.95)	0,88 (0.85–0.89)	0.007
Dip Na	0.028 (−0.007–0.054]	0.048 (0.021–0.071)	0.16
Ca125 U/min	23 (10–28)	163 (86–227)	<0.0001
Δ Ca125	−52 (−79–−13)	0 (−29–53)	0.004